VolitionRX Ltd. (NYSE: VNRX) has published a new corporate presentation highlighting its focus on licensing its proprietary epigenetics-based diagnostic technologies targeting cancer and sepsis. The company reports a proven licensing model validated in the veterinary market, with multiple products already launched and a strong intellectual property portfolio consisting of 56 patent families and 71 granted patents with coverage up to 2044. The presentation outlines VolitionRX’s commercialization strategy, which is based on an asset-light business model leveraging commercial partnerships and out-licensing agreements. The approach includes upfront and milestone payments, recurring revenue from sales of key components, and royalties. VolitionRX is currently in confidential licensing discussions with about 10 large diagnostic and liquid biopsy companies worldwide, with initial agreements signed in the third quarter of 2025. Key markets addressed include multi-billion dollar opportunities in cancer screening, sepsis management, animal health, and research use. The company's platform is described as low-cost, scalable, and adaptable to various diagnostic workflows, with products ranging from manual to point-of-care tests. Projected catalysts include multiple licensing deals in 2025 and 2026, sales growth of CE-marked products in Europe, automation of tests, and adoption into national screening programs and routine clinical practice. You can access the full presentation through the link below.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. VolitionRX Ltd. published the original content used to generate this news brief on January 08, 2026, and is solely responsible for the information contained therein.